**Merck: Wall Street Surprised By Q3 Strength, Keytruda Sales Surge**
*By ALLKA Research*
Merck published its financial results for Q3 2025 this morning, revealing strong performance that surprised many on Wall Street. A key driver was robust demand for Winrevair, a treatment for patients suffering from pulmonary arterial hypertension, which propelled sales to $360 million in the third quarter—a remarkable 141.6% increase year-over-year.
Among Merck’s vaccine portfolio, Capvaxive remains the shining star, generating sales of $244 million for the quarter. This represents an impressive 419.1% jump compared to the same period last year.
By reading this article, you will understand why I maintain a **Strong Buy** rating on MRK stock.
I’d like to begin our journey with a quote from *The Little Prince*:
*”It is only with the heart that one can see rightly; what is essential is invisible to the eye.”*
You might wonder, why start here? Because investing, much like life, requires us to look beyond the obvious figures and recognize the underlying strength and potential that might not be immediately visible.
—
### About ALLKA Research
With over two decades of dedicated experience in investment, ALLKA Research has been a trusted guide for individuals seeking lucrative opportunities. Our conservative approach sets us apart—we consistently identify undervalued assets across ETFs, commodities, technology, and pharmaceutical sectors.
Our mission is to simplify the complexity of investing for both seasoned investors and those just starting. Motivated by a passion to empower others financially, ALLKA Research shares well-researched, thought-provoking analyses on Seeking Alpha.
We aim to demystify the intricacies of investing and inspire confidence among our readers, fostering a community of informed investors capable of navigating markets with intelligence and understanding.
Join ALLKA Research as we continue this exciting journey of discovery and wealth creation, revealing the secrets of the financial world one insight at a time.
—
### Analyst’s Disclosure
I/we have no stock, option, or similar derivative position in any of the companies mentioned, nor do I have any plans to initiate such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it other than from Seeking Alpha. I have no business relationship with any company whose stock is mentioned in this article.
—
### Seeking Alpha’s Disclaimer
Past performance is no guarantee of future results. This article does not constitute a recommendation or advice as to whether any investment is suitable for a particular investor. The views expressed are those of the author and may not reflect those of Seeking Alpha as a whole.
Seeking Alpha is not a licensed securities dealer, broker, US investment adviser, or investment bank. Our analysts are third-party authors, including professional and individual investors, who may not be licensed or certified by any institute or regulatory body.
—
**Recommended For You**
*[Insert related articles or suggestions here]*
https://seekingalpha.com/article/4835377-merck-wall-street-surprised-by-q3-strength-keytruda-sales-surge?source=feed_all_articles
